Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETOPROFEN vs ACULAR LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Mild to moderate pain,Dysmenorrhea,Acute gouty arthritis (off-label)
FDA: Treatment of postoperative inflammation in patients who have undergone cataract surgery,Off-label: Relief of ocular pain, photophobia, and inflammation associated with corneal abrasion or refractive surgery
Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.
1 drop in the affected eye(s) four times daily
Terminal elimination half-life: 2-4 hours; clinical context: short half-life allows for quick drug clearance but requires frequent dosing; may be prolonged in elderly or renal impairment.
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Hepatic metabolism via cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C9; conjugation with glucuronic acid; minor hydrolysis to metabolites.
Primarily hepatic via CYP2C9; undergoes glucuronidation and oxidation to inactive metabolites.
Renal: ~80% (60% as glucuronide conjugates, 20% as unchanged drug); Biliary/Fecal: ~20% via bile.
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
99% bound, primarily to albumin; free fraction increases in hypoalbuminemia.
Ketorolac is highly protein bound, approximately 99% bound to plasma proteins, primarily albumin.
0.1-0.2 L/kg; clinical meaning: low Vd indicates limited tissue distribution, primarily confined to plasma and extracellular fluid; higher in elderly due to increased body fat.
The volume of distribution is approximately 0.12 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral: ~90% (capsules); Topical: 5-10% (systemic absorption); Rectal: ~80%; Intramuscular: ~100%.
Ophthalmic bioavailability is approximately 2% of the administered dose due to extensive nasolacrimal drainage and systemic absorption. Oral bioavailability of ketorolac is approximately 80-100%, but this route is not used for ophthalmic formulations.
Cr Cl >50 m L/min: no adjustment. Cr Cl 25-50 m L/min: reduce dose to 50% of normal. Cr Cl <25 m L/min: avoid use or maximum 50 mg twice daily.
No dosage adjustment required for renal impairment
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
No dosage adjustment required for hepatic impairment but use with caution in severe hepatic disease due to potential for increased systemic exposure
Children ≥6 months: oral 1-2 mg/kg/day divided every 6-8 hours; maximum 4 mg/kg/day. Not to exceed adult maximum.
Safety and efficacy in pediatric patients below 2 years of age have not been established; for children 2 years and older, same as adult dosing
Initiate at lowest effective dose (e.g., 50 mg twice daily); use short duration; monitor renal function, GI bleeding, and cardiovascular risk.
No specific dose adjustment recommended; use with caution due to increased incidence of age-related ocular conditions
Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
None
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; hepatic toxicity; use with caution in patients with asthma or history of GI bleeding.
Increased risk of bleeding and bleeding-related adverse events due to platelet inhibition,May prolong bleeding time,Cross-sensitivity with aspirin and other NSAIDs,Caution in patients with prior history of corneal epithelial defects or ocular surgery,Not for intraocular injection
History of hypersensitivity to ketoprofen, aspirin, or other NSAIDs; active peptic ulcer disease; history of gastrointestinal bleeding or perforation; severe renal impairment; severe hepatic impairment; during perioperative pain in CABG surgery.
Hypersensitivity to ketorolac tromethamine or any component of the formulation,Patients with active peptic ulcer disease, recent GI bleeding, or perforation,Patients with advanced renal disease or at risk for renal failure,Patients with known history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
Avoid alcohol as it increases the risk of GI bleeding. Taking with food may reduce gastrointestinal irritation but delays absorption.
No known food interactions for ophthalmic ketorolac. However, maintain good hydration and nutrition to support corneal healing.
First trimester: Avoid due to risk of spontaneous abortion and major congenital malformations (cardiac, gastroschisis). Second trimester: Avoid if possible; associated with oligohydramnios, constriction of ductus arteriosus. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, fetal nephrotoxicity, and periventricular hemorrhage.
Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during organogenesis resulted in increased embryofetal mortality, delayed ossification, and increased incidence of skeletal abnormalities at doses less than the maximum recommended human ophthalmic dose. However, systemic exposure following ocular administration is very low. NSAIDs are generally avoided during pregnancy, especially in the third trimester, due to the risk of premature closure of the ductus arteriosus and oligohydramnios. The risk is considered low for ophthalmic use but should be used only if clearly needed.
Compatible with caution. Small amounts excreted in breast milk (M/P ratio ~0.01-0.1). Due to risk of infant toxicity (e.g., gastrointestinal effects, renal impairment), consider alternative analgesics. Monitor infant for drowsiness, poor feeding, or rash.
It is not known whether ketorolac is excreted in human milk after ophthalmic administration. Systemic levels are low, and following oral administration, ketorolac is excreted in breast milk at low concentrations (M/P ratio approximately 0.37). Due to the potential for adverse effects on the nursing infant, caution should be exercised. The low systemic absorption likely poses minimal risk.
No specific dose adjustments recommended; use lowest effective dose for shortest duration. Increased clearance in pregnancy may necessitate dose adjustment, but avoid in third trimester. Use with caution in first and second trimesters due to maternal volume expansion and increased renal clearance.
No dosing adjustments are necessary for ophthalmic use during pregnancy due to negligible systemic absorption. Standard dosing (1 drop in the affected eye(s) four times daily) is recommended. Systemic NSAIDs may require dose adjustment due to increased volume of distribution and renal changes, but this does not apply to topical ocular ketorolac.
Maximum analgesic effect occurs at 50 mg oral doses; higher doses increase GI toxicity without additional pain relief. Use with caution in patients with renal impairment as ketoprofen decreases renal blood flow. Avoid use with other NSAIDs, including aspirin, due to increased ulcer risk. Ketoprofen is highly protein-bound; monitor for displacement interactions with warfarin and oral hypoglycemics.
ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and photophobia following corneal refractive surgery. Use with caution in patients with known bleeding tendencies or those on anticoagulants due to increased risk of ocular bleeding. Avoid concurrent use with other NSAIDs or steroids to minimize corneal adverse effects. Monitor for corneal epithelial breakdown or delayed healing.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; taking more does not provide extra pain relief.,Avoid alcohol while taking this medication.,Contact your doctor immediately if you experience black or bloody stools, chest pain, or signs of an allergic reaction.,Do not take with other NSAIDs or aspirin without consulting your healthcare provider.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Use only in the affected eye(s) as prescribed; do not use for longer than directed.,Temporary stinging or burning may occur upon instillation.,Report any persistent pain, redness, or visual changes to your doctor immediately.,Avoid driving or operating machinery if vision is blurred after use.
"The concurrent use of ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), with gemeprost, a synthetic prostaglandin E1 analogue used for cervical ripening and induction of labor, may antagonize the therapeutic effects of gemeprost. Ketoprofen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which directly opposes the prostaglandin-mediated actions of gemeprost, such as cervical softening and uterine contraction. This pharmacodynamic antagonism can lead to decreased efficacy of gemeprost in achieving cervical ripening or inducing labor, potentially prolonging the induction-to-delivery interval or necessitating alternative interventions."
"Amodiaquine inhibits CYP2C9, the primary enzyme responsible for metabolizing ketoprofen. This results in decreased clearance and elevated plasma concentrations of ketoprofen, increasing the risk of dose-dependent adverse effects such as gastrointestinal bleeding, renal impairment, and central nervous system toxicity. Clinically, patients may experience heightened analgesic and anti-inflammatory effects, but also a greater propensity for NSAID-related toxicity."
"Lumacaftor, a strong cytochrome P450 (CYP) 3A4 inducer, significantly decreases the systemic exposure of ketoprofen, a CYP3A4 substrate, by increasing its hepatic metabolism. This interaction can lead to reduced ketoprofen plasma concentrations, potentially compromising its analgesic and anti-inflammatory efficacy. Clinically, patients may experience suboptimal pain relief or require alternative pain management strategies."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETOPROFEN vs ACULAR LS, answered by our medical review team.
KETOPROFEN is a NSAID that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.. ACULAR LS is a NSAID Ophthalmic that works by Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETOPROFEN and ACULAR LS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETOPROFEN is: Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.. The standard adult dose of ACULAR LS is: 1 drop in the affected eye(s) four times daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KETOPROFEN and ACULAR LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KETOPROFEN is classified as Category D/X. First trimester: Avoid due to risk of spontaneous abortion and major congenital malformations (cardiac, gastroschisis). Second trimester: Avoid if possible; associated with oligohy. ACULAR LS is classified as Category C. Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during org. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.